Pharmaceuticals and Medical Devices Non-Executive Recruitment

Pharmaceuticals and Medical Devices Non-Executive Recruitment

Few sectors combine regulatory intensity, scientific complexity and commercial pressure the way pharmaceuticals and medical devices do. A life sciences board has to govern clinical trial risk, regulatory approval pathways, post-market surveillance, intellectual property and the capital intensity of developing a product, often years before any revenue arrives. Non-executive directors in this sector need more than general boardroom experience. They need enough scientific, regulatory and commercial understanding to ask the right questions, and enough independence to keep asking them when the answers are uncomfortable.

NED Capital recruits non-executive directors, chairs and committee chairs for pharmaceutical, biotech, diagnostics and medical device businesses. That includes clinical-stage companies, university spin-outs, venture and private equity-backed scale-ups, listed life sciences companies and the UK boards of international groups. This page sits alongside our wider healthcare and life sciences NED recruitment service and our non-executive director recruitment practice. Searches are run by our senior search team under founder Adrian Lawrence FCA.

What Pharma and Medical Device Boards Have to Govern

Regulatory and clinical risk

The defining feature of a life sciences board is regulatory exposure. In the UK, medicines and medical devices are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA), which authorises clinical trials, licenses medicines and oversees the safety of devices on the market. Companies with international ambitions also have to plan for the European Medicines Agency and other regulators. The board does not run the regulatory strategy, but it does have to understand it well enough to judge whether the plan is realistic, whether the timeline is credible and what happens to the business if an approval is delayed.

Clinical trial governance is a board matter too. Trials carry patient safety, data integrity and reputational risk, and the MHRA’s guidance on managing clinical trial authorisations and reporting safety issues sets obligations the board needs assurance on. A non-executive who has seen trials run, or seen them go wrong, can test the quality of that assurance in a way a generalist cannot.

Market access and commercial judgement

Approval is not the same as commercial success. A product also has to be adopted, priced and reimbursed. In England, the appraisals of the National Institute for Health and Care Excellence (NICE) shape whether the NHS uses a medicine or technology, and procurement routes into the NHS are slow and complex. Life sciences NEDs need to be able to challenge R&D investment decisions, licensing and partnering strategy, pricing and market access plans, and the timing of international expansion. The strongest candidates combine scientific or regulatory literacy with hard commercial judgement about where value is actually created.

Financing and capital discipline

Clinical-stage businesses consume capital for years before they are profitable. Non-executives need to understand the financing cycle: venture rounds, grant funding such as that from UK Research and Innovation, milestone payments, licensing deals and, for some companies, a public listing. Oversight of cash runway, dilution and the use of each funding round is one of the most important things a life sciences board does. Our page on private equity and venture-backed NED recruitment covers the investor side of these boards in more detail.

Quality, safety and post-market obligations

For medical device and diagnostics companies in particular, quality management and post-market surveillance continue long after a product is launched. Recalls, field safety notices and vigilance reporting can quickly become board-level crises. A board needs at least one director who understands quality systems well enough to know which questions to ask before something goes wrong, not after.

Intellectual property and partnering

Much of the value of a life sciences company sits in its patents, data and know-how. The board has to oversee the IP strategy, freedom-to-operate risk and the terms of licensing and co-development deals that may define the company’s future. Directors who have negotiated or governed such partnerships bring a perspective that is hard to find elsewhere.

The Non-Executive Profiles Life Sciences Boards Look For

Most boards in this sector need a blend of profiles rather than a single type of director. The appointments we are most often asked to make include:

• Chairs with life sciences board experience who can lead an investor-heavy board, manage the relationship with a scientist-founder and prepare the company for a sale, a partnership or an IPO. See our non-executive chair recruitment service.
• Regulatory and clinical non-executives with senior experience in regulatory affairs, clinical development or medical leadership in pharma, biotech or devices.
• Commercial non-executives who have launched products, built market access functions or led international commercial expansion.
• Audit committee chairs with recent and relevant financial experience, often chartered accountants with life sciences or high-growth company backgrounds. Our audit committee chair recruitment page explains the role.
• Remuneration committee chairs who understand equity-heavy pay in scale-ups and the expectations of institutional investors in listed companies. See remuneration committee chair recruitment.
• Technology and data non-executives for companies building digital health, AI-driven discovery or connected devices, overlapping with our technology NED recruitment work.

Industry bodies such as the Association of the British Pharmaceutical Industry (ABPI), the Association of British HealthTech Industries (ABHI) and the BioIndustry Association are useful reference points for the issues boards in each part of the sector are dealing with, and many strong candidates are active in them.

Boards at Different Stages

Spin-outs and early-stage companies

University spin-outs and early-stage biotechs usually start with a founder-scientist, an investor director or two and little formal governance. The first independent appointment is often a chair who can professionalise the board and help the founders work with investors. Our guide to building your first board as a scale-up covers the common choices. Many of these companies grow out of the research clusters around Cambridge and Oxford, and we recruit for boards in both.

Venture and private equity-backed scale-ups

As a company moves into later-stage trials or commercial launch, investors expect a stronger board with genuinely independent directors, functioning audit and remuneration committees and directors who have scaled a life sciences business before. The board’s focus shifts from science to execution, funding and exit options.

Listed life sciences companies

Listed companies have to meet the requirements of the UK Corporate Governance Code or, on AIM, usually the QCA Corporate Governance Code. That brings independence requirements, committee structures and investor scrutiny on top of the sector’s regulatory demands. Our listed company NED recruitment page sets out what that involves.

UK boards of international groups

Overseas pharmaceutical and device groups often need independent directors on their UK subsidiary boards to provide local governance, regulatory understanding and a credible voice with UK stakeholders. These roles call for directors who can work within group structures while still exercising independent judgement.

How We Run a Life Sciences NED Search

Every search starts with the board rather than the vacancy. We look at the company’s stage, pipeline, funding position and regulatory path, and at the skills the current directors already bring. A board skills matrix is often the quickest way to show where the gap is.

We then map candidates across pharmaceutical and biotech companies, medical device and diagnostics businesses, contract research and manufacturing organisations, life sciences investors, regulators and the NHS. Most of the strongest candidates are already serving on boards or in senior executive roles and are not looking at adverts, so we approach them directly and in confidence.

Each candidate is assessed on two things: their technical credibility in the areas the board needs, and their effectiveness as a non-executive. That second test matters. Excellent scientists and regulatory leaders do not always make effective board members, and we test candidates for independence of mind, the ability to challenge constructively and the time they can commit. We check conflicts of interest carefully, because life sciences is a sector where candidates often hold roles with competitors, investors or suppliers.

We work in line with the voluntary code of conduct for executive search firms, and the timeline and fee structure are agreed before any search begins. For an indication of typical NED pay, see our NED salary guide.

Frequently Asked Questions

Does a life sciences NED need a scientific background?
Not always. Some seats call for regulatory or clinical depth, others for financial, commercial or listed-company experience. What matters is the balance across the board. Every director needs enough understanding of the science and regulation to engage with the key decisions.

Do you recruit for medical device and diagnostics companies as well as pharma?
Yes. Device and diagnostics boards face different regulatory and quality questions from pharmaceutical boards, and we recruit directors with experience specific to each.

Can you recruit a chair for a university spin-out?
Yes. A first independent chair is one of the most common appointments for early-stage life sciences companies, and we help define the role with the founders and investors before the search starts.

Do you work outside the Golden Triangle?
Yes. We recruit across the UK from our offices in London and the West Midlands.